Navigation Links
Addition of trastuzumab may potentially equalize disease-free survival outcomes among obese and normal-weight patients
Date:12/8/2011

SAN ANTONIO A large, multicenter, randomized study has shown that obese patients with HER2-positive breast cancer have larger tumors, increased lymph node involvement and, when not treated with trastuzumab, poorer long-term outcomes than normal-weight patients.

This is the first time the relationship between obesity and HER2-positive breast cancer has been studied, according to Jennifer A. Crozier, M.D., a medical resident at Mayo Clinic, Jacksonville, who presented the results at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

"We knew that obesity was a risk factor for breast cancer," said Crozier. "However, we had not explored the relationship between body mass and how patients respond to treatment and disease-free survival (DFS)."

The study, known as N9831, included 3,017 patients who were initially classified into two categories based on World Health Organization body mass index (BMI) guidelines: normal-weight patients (BMI less than 30) and obese patients (BMI greater than 30). BMI was measured when patients began chemotherapy.

Researchers randomly assigned patients to treatment with only chemotherapy, with chemotherapy and sequential trastuzumab or with chemotherapy and concurrent trastuzumab.

When data were first examined, there were no significant differences in DFS between obese and normal-weight patients in any arm at three, five and seven years of follow-up. The team then subdivided normal-weight patients to determine if those patients considered overweight, with BMI between 25 and 29, might be affecting the analysis.

They found that obese patients and overweight patients had lower DFS rates of 70.6 percent and 65.9 percent, respectively, after seven years when not treated with trastuzumab compared with a rate of 74.7 percent among normal-weight patients also treated with chemotherapy alone. Results suggested that adding trastuzumab to treatment, particularly when received concurrently with chemotherapy, may potentially equalize DFS rates, with five-year rates of about 85 percent for normal-weight and overweight patients and 82.6 percent for obese patients.

Researchers observed these DFS rates among patients who received concurrent trastuzumab, regardless of BMI. Among patients treated with sequential trastuzumab, normal-weight patients appeared to have benefited more from the treatment than obese patients. Patients treated with chemotherapy alone had the worst observed DFS rate of the three groups, highlighting the potential importance of trastuzumab in treating HER2-positive breast cancer.

The researchers also alleviated the concern that hormonal differences in obese patients might undercut trastuzumab's effectiveness.

"Overall, we can see in the trends that weight management is going to be important in treating HER2-positive breast cancer," said Crozier. "The next step is to examine how weight management during different stages of treatment affects outcomes."


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. BIO-key(R) Announces Additional $245,000 in Third Quarter Public Safety Orders
2. BIO-key(R) Granted Additional Patent for Biometric Security Solution
3. Nine Additional Virginia Law Enforcement Agencies Deploy BIO-key(R) and DaPro Systems Solution
4. Nine Additional Virginia Law Enforcement Agencies Deploy BIO-key(R) and DaPro Systems Solution
5. Fujitsu Expands Support for Ethernet Networks With New Additions to XG Switch Product Line
6. Small addition to cancer drug may make big difference
7. Extinction of woolly mammoths may have been due to addition of a predator: Humans
8. BIO-key® Awarded Additional Large-Scale Fingerprint Biometric Contract
9. Connection between light at night (LAN) and cancer revealed in additional study
10. Connection between light at night and cancer revealed in additional study
11. Study finds massive flux of gas, in addition to liquid oil, at BP well blowout in Gulf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/18/2016)... 18, 2016 --> ... ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance ... in the border security market and the continuing migration crisis ... Europe has led visiongain to publish this ... --> defence & security companies in the ...
(Date:3/14/2016)... March 14, 2016 NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ... week of March 21 st .  The commercials will air ... popular Squawk on the Street show. --> NXTD ... growing mobile commerce market, announces the airing of a new ...
(Date:3/10/2016)... 10, 2016 --> ... report "Identity and Access Management Market by Component (Provisioning, ... Governance), by Organization Size, by Deployment, by Vertical, and ... MarketsandMarkets, The market is estimated to grow from USD ... 2020, at a Compound Annual Growth Rate (CAGR) of ...
Breaking Biology News(10 mins):
(Date:5/23/2016)... Oxitec CEO Hadyn Parry will testify ... before the United States House Committee on Science, Space and ... controlling the spread of the Aedes aegypti mosquito, ... (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) Oxitec has pioneered ... in Brazil , Panama ...
(Date:5/22/2016)... , ... May 22, 2016 , ... Doctors in Rome ... combating the asbestos cancer, malignant mesothelioma. Surviving Mesothelioma has just posted an article on ... the University of Rome’s Department of Clinical Sciences and Translational Medicine evaluated more than ...
(Date:5/20/2016)... ... 20, 2016 , ... The recent recall by Costco and Trader Joes of ... on May 12, 2016(1), demonstrates the need for faster and more cost effective bio-threat ... PathSensors, Inc. , PathSensor’s latest solution uses a biosensor technology called ...
(Date:5/19/2016)... ... May 19, 2016 , ... KCAS Bioanalytical and Biomarker ... as Director, Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more than ... studies for preclinical and clinical safety programs. “We’ve seen significant demand for, and ...
Breaking Biology Technology: